In this episode of the Oncology Brothers podcast, we had the pleasure of discussing the recent FDA approval of datopotamab deruxtecan (Dato-DXd) for previously treated EGFR-mutated non-small cell lung cancer (NSCLC). We were joined by Dr. Jacob Sands, a thoracic medical oncologist from the Dana-Farber Cancer Institute, who played an active role in the TROPION lung trials that led to this approval.
We began by setting the stage for the current treatment landscape for EGFR-mutated NSCLC, highlighting the limited options available once the disease progresses. Dato-DXd represents a significant advancement, as it is the first TROP2 antibody-drug conjugate approved for this indication, providing new hope for patients.
Dr. Sands explained the mechanism of Dato-DXd, which involves an antibody targeting the TROP2 receptor on tumor cells, leading to the internalization and release of a cytotoxic payload. We delved into the study design of the TROPION Lung trials, which included a diverse patient population and demonstrated promising efficacy and tolerable toxicity profiles.
Key findings from the trials showed a median progression-free survival of 5.8 months and an overall survival of 15.6 months in the EGFR-positive cohort, with fewer dose reductions and discontinuations compared to traditional chemotherapy options. We also discussed the side effects associated with Dato-DXd, such as stomatitis, dry eyes, and the potential risk of interstitial lung disease (ILD), emphasizing the importance of patient management and prophylactic measures.
As we wrapped up, we explored the complexities of sequencing treatments for EGFR-mutated NSCLC, particularly in light of ongoing studies like FLAURA-2. Dr. Sands shared his insights on how he plans to incorporate Dato-DXd into his practice, considering the nuances of each patient's treatment history.
Overall, this episode provided valuable insights into a new treatment option for patients with EGFR-mutated NSCLC.